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Summary
The most frequent complication of A (H1N1) influenza and the leading cause of death was pneu-
monia with a primary viral or mixed viral and bacterial etiology. 182 patients had died because of 
a pandemic influenza in Poland by 31st July 2010.
A retrospective study of 6 fatal cases of pandemic influenza, aged 23-41, including 3 women, hospi-
talised between November 2009 and February 2011 in different Polish medical centres. 
We present the clinical course of 6 late diagnosed cases of A (H1N1) influenza. All patients presen-
ted typical flu-like symptoms in the beginning. 4/6 patients had severe disease risk factors: pre-
gnancy, arthritis, Wegener granulomatosis and obesity. All patients were seen by doctors, no one 
had received antiviral therapy, 4/5 were treated with antibiotics before they were hospitalized. One 
patient had nosocomial infection. Patients were admitted to the hospital on the 3rd to 8th day of the 
disease. They received oseltamivir treatment on the 4th to 9th day. All patients developed pneumo-
nia complicated by acute respiratory distress syndrome. Death appeared between the 4th and 27th 
day after the onset of symptoms. Autopsies were performed in 5 cases and revealed haemorrhagic 
pneumonia in 2 patients.
Delayed diagnosis and antiviral treatment initiation has a significant impact on mortality in A (H1N1) 
influenza. During the influenza epidemic, patients presenting typical symptoms should always be 
suspected of having influenza. Antiviral treatment has to be initiated immediately, especially if 
there are risk factors of severe disease. 
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IntroductIon
In April 2009, in Mexico, there was an outbreak of a new A 
(H1N1) influenza virus [5]. The virus spread rapidly world-
wide. The highest level of an influenza pandemic was an-
nounced by the WHO on 11th June 2009 [23]. Spain was the 
first European country with a laboratory to confirm a H1N1 
influenza pandemic [18]. Mortality in H1N1 cases was similar 
to that of seasonal influenza [3,20]. The first case in Poland 
was documented on 6th May 2009. The highest incidence of 
H1N1 influenza occurred in November and December 2009. 
A total of 182 patients had died because of A (H1N1) influ-
enza by 31st July 2010 [4]. As some studies showed, pan-
demic influenza was different to the seasonal one. It mainly 
concerned relatively young people (under the age of 60), 
who were relatively healthy beforehand. As with seasonal 
influenza, people with underlying health conditions and 
pregnant women were in the group with an increased risk 
of a severe disease. Obesity and delayed antiviral treatment 
have been identified as major risk factors of a severe out-
come and higher mortality [6,7,11,14,16,19,20,22]. The most 
frequent complication in H1N1 influenza was pneumonia 
with a primary viral or mixed viral and bacterial aetiology 
(especially Streptococcus pneumoniae and Staphylococcus au-
reus) [7,13,14,22]. Death usually occurred as a result of acute 
respiratory distress syndrome (ARDS) [7,14,17]. During the 
influenza H1N1 pandemic, due to the infection’s prophylaxis 
limitations, the crucial tasks were prompt diagnosis, assess-
ing the risk of severe disease and the immediate initiation 
of adequate antiviral therapy.
MaterIal and Method
A retrospective analysis of six fatal cases during the A (H1N1) 
influenza pandemic of patients hospitalised between No-
vember 2009 and February 2011 in different Polish medical 
centres was performed. All patients were confirmed with 
2009 H1N1 influenza by rRT-PCR – using pharyngeal or na-
sopharyngeal swabs. The study protocol included the fol-
lowing information: age, sex, comorbid conditions, contact 
with people with acute respiratory infection, the time from 
the onset of symptoms to the first visit to the doctor, num-
ber of visits to the doctors until hospitalisation, the time 
from the onset of symptoms until hospitalisation, the time 
from hospital admission to ICU admission, the time spent in 
hospital, the time from the onset of symptoms to death, and 
the time from the onset of symptoms to the initiation of an-
tiviral therapy. The study protocol comprised data included 
in medical records as well as testimony provided by medical 
staff and patients’ family members during court proceedings 
on the alleged malpractice. Obesity was defined as a BMI ≥30. 
We recorded the clinical course – signs, symptoms, selected 
laboratory results, blood gas analysis, radiological findings 
and the history of treatment.
results
Clinical characteristics
We describe 6 fatal cases of 2009 H1N1 influenza, treated in 
6 different Polish hospitals from November 2009 to Febru-
ary 2010. The age of the patients ranged from 23 to 41 years. 
There were 3 males and 3 females. Four patients had under-
lying conditions – one had unidentified chronic arthritis 
treated with methylprednisolone, one was newly diagnosed 
with Wegener granulomatosis treated with methylpredniso-
lone and cyclophosphamide, one was pregnant (31 weeks) 
and one was extremely obese (BMI 40). The others did not 
have any identifiable risk factors of any severe disease. Four 
patients had family contact with people who had a flu-like 
illness (H1N1 not confirmed). One patient with Wegener 
granulomatosis was infected during hospitalisation in the 
Table 1. Symptoms observed in patients with A (H1N1) influenza before hospitalization
Symptoms Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Fever
38-39°C
39.1-40°C
+ + +
+
+
+
Cough + + + + + +
Sore throat + + + +
Haemoptysis + +
Rhinorrhoea +
Fatigue + + + + + +
Myalgia/arthralgia + + + +
Nausea, vomiting + +
Diarrhoea + +
Headache +
Chest pain + 
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internal medicine and nephrology department; therefore, 
the study protocol does not fully apply to this case. None of 
the patients had been vaccinated against pandemic H1N1 
influenza. The duration of symptoms before the first visit to 
the doctor ranged from 1 to 4 days. The duration of symp-
toms before hospitalisation ranged from 3 to 8 days. None of 
the patients received antiviral treatment before admission 
to hospital, though all of them sought medical help several 
times (ranging from 3 to 5 times). All patients had a fever 
over 38°C, a cough and fatigue before admission to hospital 
– 4 complained of a sore throat and myalgia/arthralgia, 2 
complained of nausea/vomiting, 2 had diarrhoea (Table 1).
The other symptoms were rhinorrhoea, haemoptysis, head-
ache and chest pain. The patients were diagnosed with phar-
yngitis, tracheitis, bronchitis, viral infection, respiratory 
infection and in one case seasonal influenza. The first symp-
toms of influenza in the patient with Wegener granuloma-
tosis were fever, fatigue and diarrhoea. After 2 days, the 
cough and dyspnoea appeared. In 5 cases, the main cause for 
visiting the hospital was lack of improvement in the physi-
cal condition or intensification of symptoms despite the 
treatment. Upon admission, 3 patients had dyspnoea and 2 
had auscultatory phenomena. During hospitalisation, all the 
patients developed respiratory failure and required inten-
sive care. The time from hospital admission to ICU transfer 
was < 12 h in 3 out of 5 cases. Consequently, the interval 
between the onset of symptoms and ICU admission ranged 
from 6 to 9 days. The patient with Wegener granulomatosis 
required mechanical ventilation after 3 days of symptoms. 
He was also haemodialysed because of kidney failure, which 
appeared during the course of the underlying disease (be-
fore the influenza).
Diagnostics
In all patients, at the time of hospital admission, we found ab-
normalities in their blood morphology (Table 2). 4/5 patients 
had lymphopenia with normal total white blood counts and 
2/5 had thrombocytopenia. The patient with Wegener granu-
lomatosis had pancytopenia because of his underlying dis-
ease. C-reactive protein concentration was elevated in all 
cases, but in one case it was extremely high (422 mg/dl). 
Slightly increased liver transaminase activity (GOT – glu-
tamic oxaloacetic transaminase; and GPT – glutamic pyruvic 
transaminase) was found in 2 patients – one was extremely 
obese and developed liver failure during hospitalisation. In 
all cases, blood gas analyses proved hypoxemia, which per-
sisted regardless of oxygen therapy. All patients had chest 
X-rays on the day of hospital admission and they all had bi-
lateral infiltrates indicating pneumonia.
All patients were tested for A (H1N1) influenza using real 
time PCR. In 2 cases, a rapid influenza test was performed 
– the results were negative. Microbiology diagnostics re-
vealed bacterial superinfection in 2 cases. In the first pa-
tient, Staphylococcus aureus MLSB (+) was isolated from the 
sputum. In the second (the patient with Wegener granulo-
matosis), Acinetobacter baumannii sensitive to cefoperazone 
and colistin was isolated from the blood. The patient with 
Wegener granulomatosis also had CMV reactivation (CMV 
DNA in the blood).
Table 2. Diagnostic findings
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Leukocyte count
< 4 x 103/µl
4-10 x 103/µl
> 10 x 103/µl
+ + + + +
+
Lymphopenia
<1.5 x 103/µl + + - + + +
Anaemia Hb<12g/dl - - - -
+ (during 
pregnancy)
+
Thrombocytopenia <150 x 
103/µl - - + - + +
CRP mg/dl No data 16.63-23.28 50 422 75.1-221.03 >90
AspAT No data 81-1868 75 - Normal Normal
AlAT No data 74-718 58 - Normal Normal
Creatinine No data Normal Normal - Normal Haemodialysis
Rapid test H1N1 influenza Not made Negative Not made Negative Not made Not made
Chest X-ray
Inflammatory 
changes
Inflammatory 
changes
Inflammatory 
changes
Inflammatory 
changes
Inflammatory 
changes
Inflammatory 
changes, 
cardiomegaly
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Treatment
Four patients were treated with antibiotics before admission to 
hospital. One person received one type and 3 patients received 
two types of antibiotics. The most commonly used antibiotic 
was cefuroxime, which was administered in 3 cases. The other 
antibiotics were doxycycline, amoxicillin, azithromycin and 
gentamicin. In all cases, the antibiotic therapy was changed 
or initiated after hospital admission. Three patients received 
cefuroxime (in one case cefuroxime plus amikacin), 3 received 
amoxicillin with clavulanic acid – in one case ciprofloxacin and 
in another erythromycin was added. All patients also received 
oseltamivir. The time from the onset of the illness to the initia-
tion of oseltamivir therapy was 7-9 days. None of the patients 
were given the test for the resistance of the H1N1 influenza vi-
rus to oseltamivir. The patient with Wegener granulomatosis 
was initially treated with amoxicillin with clavulanic acid and 
ciprofloxacin. After two days cefuroxime was added, which 
was changed to another antibiotic – imipenem. The time from 
the onset of illness to the initiation of oseltamivir therapy was 
4 days. All patients were treated in the ICU because of respira-
tory distress. They all required mechanical ventilation. In the 
pregnant woman, because of impaired oxygenation, a caesar-
ean section was performed. In this case, high frequency oscil-
latory ventilation and ventilation in the supine position were 
also used. Interventions such as ECMO or extracorporeal CO2 
removal were not used in any case.
Death
Death appeared between the 4th and 27th day after the on-
set of symptoms – later in patients without severe course 
risk factors. All patients developed acute respiratory distress 
syndrome (ARDS). The final cause of death in 4 patients was 
cardiorespiratory failure. In 2 patients it was multi-organ 
dysfunction syndrome. Autopsies were performed in 5 cases, 
all by a pathologist. The post-mortem examination was not 
performed in the patient with Wegener granulomatosis. In 
all cases the autopsy revealed features of pneumonia. In two 
cases haemorrhagic pneumonia was found (in one of them an 
image of purulent pneumonia), in two others lung fibrosis. 
In the obese patient and the pregnant woman, liver steatosis 
was also diagnosed.
dIscussIon
We have presented six fatal cases of pandemic (H1N1) influ-
enza relating to patients who were hospitalised in Poland be-
tween November 2009 and February 2010. All patients devel-
oped pneumonia and consequently ARDS, and they required 
treatment in the ICU. All our patients were young – age ranged 
from 23 to 41 years. As many studies have shown, the H1N1 in-
fluenza virus mostly infected people between 60 and 65 years 
old [6,7,11,14,17,19,20,22,25].
In our study, 4 patients had risk factors of severe diseases: chron-
ic arthritis, Wegener granulomatosis, pregnancy and obesity. 
Despite many disturbing reports on the dramatic increase in 
the number of overweight/obese people (obesity epidemic) and 
the health consequences of this condition [8,15], excessive body 
weight is still commonly perceived as a physiological status – 
a variant of the norm. People rarely recognize the correlation 
between obesity and the prevalence of chronic, more infectious 
diseases. In pandemic influenza cases, excessive body weight 
has proved to be a very important risk factor of severe illness, 
associated with higher mortality [6,7,11,20,22]. For example in 
the Cui et al. [6] study 32% and in the Viasus et al. [22] study 
28% of hospitalised patients were obese.
The next risk factor was pregnancy. The studies showed that the 
mortality in the severe course of H1N1 influenza in pregnant 
women was up to 20% [19,20,22,25]. High risk of influenza with 
a poor outcome during pregnancy was associated with respira-
tory, cardiac and immune system changes [9]. It was higher in 
women with chronic diseases, especially with asthma and obe-
sity. Complications occurred more often in the second and third 
trimester of pregnancy and in multigravida patients [11,16,25]. 
During the pandemic, the rate of premature birth also increased 
– 30.2% in the Siston et al. [16] study and 57.8% in the Zhang et 
al. [25] study. This was clearly associated with a higher rate of 
neonatal death [16,25].
In our study, two patients had pre-existing medical conditions, 
which predispose to a poor outcome. In one case, it was chronic 
arthritis which appeared in the course of the undetermined sys-
temic disease. The woman was treated with steroids for several 
months. Based on the medical records, the authors established 
that the patient was not treated regularly and her ailments, 
in the period preceding the A (H1N1) infection, were exacer-
bated. The second patient was immunocompromised because 
of Wegener granulomatosis. Many authors have presented the 
relation between the severity of the influenza, the higher death 
rate and pre-existing medical conditions. Besides obesity, the 
most common underlying medical conditions were asthma, 
chronic obstructive pulmonary disease, diabetes, cardiac and 
liver diseases, neoplasms, renal failure and immunosuppres-
sion [6,7,11,14,17,19,22]. Tabarasi et al. [19] also highlighted 
drug abuse.
The other important risk factor which influenced the mortal-
ity rate during the pandemic was bacterial co-infection. The 
most common identified strains were Streptococcus pneumoniae 
and Staphylococcus aureus [7,11,13,22]. In our study, one patient 
had pneumonia caused by a coexisting H1N1 virus and Staphy-
lococcus aureus. In the patient with Wegener granulomatosis, 
Acinetobacter baumannii was isolated from the blood. Because of 
immunosuppressive treatment, he also had CMV reactivation. 
Viasus et al. [22] showed that early treatment with oseltamivir 
was associated with less evidence of pneumonia and bacterial 
co-infections. 
In our data, the clinical features of influenza included fever, 
cough, fatigue, sore throat, myalgia or arthralgia, nausea/vom-
iting, diarrhoea, rhinorrhoea, haemoptysis, headache and chest 
pain. These symptoms have also been reported in many other 
studies [6,7]. The laboratory tests performed upon admission 
showed lymphopenia and thrombocytopenia and the CRP level 
was elevated in each case. Many authors have reported the as-
sociation between increased CRP concentration or lymphopenia 
and severe illness [14].  
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In our study group, the H1N1 2009 influenza infection was con-
firmed by an rRT-PCR assay. Only 2 patients had a rapid test for 
H1N1 influenza and in both cases the result was negative. In 
these cases it was the reason for a one-day delay in treatment. 
A number of studies have proven the rapid tests to have too low 
sensitivity. Thus, further proceedings should not be dependent 
on their negative results [11,21]. The rRT-PCR is the most sen-
sitive and specific influenza diagnostic test but false negatives 
can also occur. According to the CDC the sensitivity in an rRT-
PCR assay is 86-100% [1].
During the pandemic, the CDC recommended introducing ear-
ly empiric antiviral therapy with oseltamivir in patients with 
flu-like symptoms without undue delay (without waiting for 
the test result or the symptoms of severe disease), especially 
in patients who were at increased risk of complications from 
influenza [2]. The therapy was most effective if it was initiated 
within 48 hours from the onset of symptoms [2,24]. Despite this, 
there were studies that provided evidence that treatment with 
oseltamivir in patients admitted to hospital even after 48 hours 
may reduce mortality [11,12,24]. Late initiation of therapy was 
clearly associated with a higher risk of severe illness and mor-
tality [16,19,22]. In all our cases, the initiation of treatment was 
significantly delayed. It was caused by the fact that the doctors, 
despite the typical flu-like symptoms, did not suspect a H1N1 
infection at the very beginning of the illness. The diagnosis 
of pandemic influenza was only made during hospitalisation. 
Polish recommendations for the management of patients sus-
pected of having H1N1 influenza were not precise [10]. As a re-
sult, many doctors did not know how to deal with such patients.
None of our patients were vaccinated. In Poland, due to the Min-
ister of Health’s decision, a vaccine against H1N1 influenza was 
not available, even for healthcare workers. Therefore, preven-
tive options were limited. The therapeutic options in patients 
with severe disease (hospitalised in the ICU) were also limited. 
Unconventional therapies such as ECMO, high frequency os-
cillatory ventilation or extracorporeal CO2 removal were only 
available in a few hospitals in the country, access to these cen-
tres was limited and experience in the use of these therapies 
in influenza cases was poor.
We excluded one case of a pregnant woman (22 weeks) 
from the report. The patient was admitted to the hospi-
tal in December 2009 with influenza-like symptoms: fever 
up to 40°C, sore throat, cough, fatigue, myalgia and ar-
thralgia, and dyspnoea, and also complaints about dysuric 
symptoms. The disease lasted 2 days. Upon admission, the 
patient had peripheral cyanosis and disturbances in blood 
gas analyses (hypoxemia and acidosis). She also had a uri-
nary tract infection. She was treated with oseltamivir (from 
the first day of hospitalisation) and antibiotics. In this case 
both the rapid test and PCR were negative. Her condition 
deteriorated in a couple of days; she developed ARDS and 
required intensive care with mechanical ventilation in the 
ICU. During transportation to the other department, she 
had a cardiac arrest. The ultrasound performed during the 
resuscitation revealed a rupture of the spleen (perhaps af-
ter cardiac massage). She died five days after the onset of 
symptoms. The autopsy revealed haemorrhagic pneumonia 
and features of pyelonephritis.
Our study has some limitations. First of all, it refers to a small 
number of cases. The group is heterogeneous and the patient 
selection was random. The other issue is the limited material in 
the histopathological reports. They only include basic informa-
tion and lack important details. The reports were prepared by 
a few different pathologists. The patients were treated in dif-
ferent hospitals and did not have the same diagnostics, so not 
all information required was collected. Nevertheless, this is a 
good illustration of problems experienced in Poland during the 
A (H1N1) influenza pandemic.
conclusIons
Delayed diagnosis and antiviral treatment initiation has a signif-
icant impact on mortality in A (H1N1) influenza. During the in-
fluenza epidemic, patients presenting typical symptoms should 
always be suspected of having influenza. Antiviral treatment 
has to be initiated immediately, especially if there are risk fac-
tors of severe disease. Diagnostic and therapeutic procedures 
should concentrate on respiratory sufficiency as pneumonia 
(viral and secondary bacterial) is a major cause of death.
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